14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026
PLSE vs DXR: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 16, 2026, Pulse Biosciences, Inc (PLSE) captures the overall head-to-head institutional edge over Daxor Corporation (DXR) on higher Unified Composite conviction (40.1/100 SELL vs. 52.2/100 HOLD) after splitting the core matrix 4–6 (led by Growth & Scale, Options & Positioning), while DXR wins 3–2 across the 6-pillar growth and valuation breakdown. PLSE trades at $46.36 (N/M Forward P/E, -5861.2% operating margin) versus DXR at $8.36 (64.5x Forward P/E, -5894.3% operating margin).
Composite vs. Pillar Nuance: While DXR currently prints a higher short-term Unified Composite Score (52.2/100 HOLD vs. PLSE 40.1/100 SELL), PLSE captures the overall institutional head-to-head verdict (4–6 matrix metrics and 2–3 across the 6 pillars) due to superior fundamental profitability (-5861.2% vs. -5894.3% operating margin) and revenue trajectory (+359.3% vs. +25.5% YoY).
Technical & Structure Timing Caution: PLSE trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 40.3); meanwhile DXR is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 31.2). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on PLSE vs DXR. Trailing 12-month operating profitability (PLSE -5861.2% vs DXR -5894.3%) and valuation multiples (PLSE N/M vs DXR 64.5x Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Medical Instruments & Supplies value chain with $49.5M market capitalization and -5894.3% operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
Investor FAQ PLSE vs DXR Key Questions & Quantitative Answers
As of Nov 16, 2026, Pulse Biosciences, Inc (PLSE) captures the overall head-to-head institutional edge over Daxor Corporation (DXR) on higher Unified Composite conviction (40.1/100 SELL vs. 52.2/100 HOLD) after splitting the core matrix 4–6 (led by Growth & Scale, Options & Positioning), while DXR wins 3–2 across the 6-pillar growth and valuation breakdown. PLSE trades at $46.36 (N/M Forward P/E, -5861.2% operating margin) versus DXR at $8.36 (64.5x Forward P/E, -5894.3% operating margin). Composite vs. Pillar Nuance: While DXR currently prints a higher short-term Unified Composite Score (52.2/100 HOLD vs. PLSE 40.1/100 SELL), PLSE captures the overall institutional head-to-head verdict (4–6 matrix metrics and 2–3 across the 6 pillars) due to superior fundamental profitability (-5861.2% vs. -5894.3% operating margin) and revenue trajectory (+359.3% vs. +25.5% YoY). Technical & Structure Timing Caution: PLSE trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 40.3); meanwhile DXR is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 31.2). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
PLSE leads the Growth & Scale pillar: PLSE posts +359.3% YoY revenue growth and +0.0% YoY earnings growth on $1.5M TTM revenue (26.8% gross margin, -5861.2% operating margin), compared with DXR at +25.5% YoY revenue growth and +329.3% YoY earnings growth on $31,360 TTM revenue (100.0% gross margin, -5894.3% operating margin). On trailing 12-month operating scale, PLSE generates $1.5M in USD-normalized revenue versus $31,360 for DXR. In operating R&D and SG&A reinvestment, PLSE deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for DXR.
DXR screens cheaper on headline valuation multiples. PLSE trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin), whereas DXR trades at 64.5x Forward P/E, 7.7x Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against PLSE (-60.6% ROE) versus DXR (14.2% ROE) capital efficiency.
In options market volatility and institutional positioning, PLSE carries 73.5% implied volatility (10th %ile, Compressed (<25th %ile)), a 0.70x (Call-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a CONSOLIDATION options structure phase (1.71β · 78% Vol realized risk). By comparison, DXR carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.28β · 32% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.